George Y Wang
Examiner (ID: 4033)
Most Active Art Unit | 2871 |
Art Unit(s) | 2882, 2871 |
Total Applications | 215 |
Issued Applications | 148 |
Pending Applications | 11 |
Abandoned Applications | 56 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 14685123
[patent_doc_number] => 20190241676
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-08-08
[patent_title] => ANTI-MERTK AGONISTIC ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/256737
[patent_app_country] => US
[patent_app_date] => 2019-01-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42450
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16256737
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/256737 | Anti-MERTK agonistic antibodies and uses thereof | Jan 23, 2019 | Issued |
Array
(
[id] => 14883581
[patent_doc_number] => 10421817
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2019-09-24
[patent_title] => Antibodies binding human Claudin 18.2 and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/254587
[patent_app_country] => US
[patent_app_date] => 2019-01-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 41
[patent_no_of_words] => 19652
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 296
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16254587
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/254587 | Antibodies binding human Claudin 18.2 and uses thereof | Jan 21, 2019 | Issued |
Array
(
[id] => 15178251
[patent_doc_number] => 20190359717
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-28
[patent_title] => ANTI-cMET ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 16/239829
[patent_app_country] => US
[patent_app_date] => 2019-01-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24115
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16239829
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/239829 | ANTI-cMET ANTIBODY | Jan 3, 2019 | Abandoned |
Array
(
[id] => 15180873
[patent_doc_number] => 20190361028
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-28
[patent_title] => FREE NGAL AS A BIOMARKER FOR CANCER
[patent_app_type] => utility
[patent_app_number] => 16/238940
[patent_app_country] => US
[patent_app_date] => 2019-01-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9535
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16238940
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/238940 | FREE NGAL AS A BIOMARKER FOR CANCER | Jan 2, 2019 | Abandoned |
Array
(
[id] => 14868075
[patent_doc_number] => 20190284279
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-19
[patent_title] => BISPECIFIC ANTIBODY BINDING TO HUMAN CD19 AND CD3
[patent_app_type] => utility
[patent_app_number] => 16/237124
[patent_app_country] => US
[patent_app_date] => 2018-12-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14719
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 106
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16237124
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/237124 | BISPECIFIC ANTIBODY BINDING TO HUMAN CD19 AND CD3 | Dec 30, 2018 | Abandoned |
Array
(
[id] => 17156153
[patent_doc_number] => 20210317204
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-14
[patent_title] => BI-SPECIFIC BINDING MOLECULES
[patent_app_type] => utility
[patent_app_number] => 16/957079
[patent_app_country] => US
[patent_app_date] => 2018-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30995
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -66
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16957079
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/957079 | BI-SPECIFIC BINDING MOLECULES | Dec 20, 2018 | Pending |
Array
(
[id] => 16688370
[patent_doc_number] => 20210070846
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-11
[patent_title] => SPECIFIC DOSAGE REGIMEN FOR HEMIBODY THERAPY
[patent_app_type] => utility
[patent_app_number] => 16/955902
[patent_app_country] => US
[patent_app_date] => 2018-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6221
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16955902
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/955902 | SPECIFIC DOSAGE REGIMEN FOR HEMIBODY THERAPY | Dec 20, 2018 | Pending |
Array
(
[id] => 17681020
[patent_doc_number] => 11365259
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-06-21
[patent_title] => IGF-1R antibody and its use as addressing vehicle for the treatment of cancer
[patent_app_type] => utility
[patent_app_number] => 16/223363
[patent_app_country] => US
[patent_app_date] => 2018-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 33
[patent_figures_cnt] => 50
[patent_no_of_words] => 32275
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 141
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16223363
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/223363 | IGF-1R antibody and its use as addressing vehicle for the treatment of cancer | Dec 17, 2018 | Issued |
Array
(
[id] => 14746839
[patent_doc_number] => 20190256593
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-08-22
[patent_title] => CD33 BINDING AGENTS
[patent_app_type] => utility
[patent_app_number] => 16/221811
[patent_app_country] => US
[patent_app_date] => 2018-12-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16876
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16221811
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/221811 | CD33 BINDING AGENTS | Dec 16, 2018 | Abandoned |
Array
(
[id] => 16506184
[patent_doc_number] => 20200385440
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-10
[patent_title] => MODIFIED BISPECIFIC T CELL RECEPTORS
[patent_app_type] => utility
[patent_app_number] => 16/769538
[patent_app_country] => US
[patent_app_date] => 2018-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39686
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -89
[patent_words_short_claim] => 187
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16769538
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/769538 | MODIFIED BISPECIFIC T CELL RECEPTORS | Dec 5, 2018 | Abandoned |
Array
(
[id] => 16438367
[patent_doc_number] => 20200355693
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-12
[patent_title] => A NEW MARKER FOR PREDICTING THE SENSITIVITY TO PI3K INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/765345
[patent_app_country] => US
[patent_app_date] => 2018-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10730
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16765345
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/765345 | Marker for predicting the sensitivity to PI3K inhibitors | Nov 21, 2018 | Issued |
Array
(
[id] => 14069467
[patent_doc_number] => 20190083621
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-03-21
[patent_title] => RS7 Antibodies
[patent_app_type] => utility
[patent_app_number] => 16/198276
[patent_app_country] => US
[patent_app_date] => 2018-11-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23135
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16198276
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/198276 | RS7 Antibodies | Nov 20, 2018 | Abandoned |
Array
(
[id] => 16452625
[patent_doc_number] => 20200362051
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-19
[patent_title] => MOLECULES THAT BIND TO CD137 AND PSMA
[patent_app_type] => utility
[patent_app_number] => 16/763063
[patent_app_country] => US
[patent_app_date] => 2018-11-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28746
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16763063
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/763063 | MOLECULES THAT BIND TO CD137 AND PSMA | Nov 12, 2018 | Pending |
Array
(
[id] => 14406867
[patent_doc_number] => 20190169277
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-06-06
[patent_title] => MODIFIED ANTI-TENASCIN ANTIBODIES AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 16/186418
[patent_app_country] => US
[patent_app_date] => 2018-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36612
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16186418
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/186418 | Modified anti-tenascin antibodies and methods of use | Nov 8, 2018 | Issued |
Array
(
[id] => 15540849
[patent_doc_number] => 10570190
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-02-25
[patent_title] => Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
[patent_app_type] => utility
[patent_app_number] => 16/175002
[patent_app_country] => US
[patent_app_date] => 2018-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 54
[patent_figures_cnt] => 18
[patent_no_of_words] => 12580
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 127
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16175002
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/175002 | Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same | Oct 29, 2018 | Issued |
Array
(
[id] => 15540849
[patent_doc_number] => 10570190
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-02-25
[patent_title] => Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
[patent_app_type] => utility
[patent_app_number] => 16/175002
[patent_app_country] => US
[patent_app_date] => 2018-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 54
[patent_figures_cnt] => 18
[patent_no_of_words] => 12580
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 127
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16175002
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/175002 | Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same | Oct 29, 2018 | Issued |
Array
(
[id] => 14929973
[patent_doc_number] => 20190300624
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-03
[patent_title] => HER3 ANTIGEN-BINDING MOLECULES
[patent_app_type] => utility
[patent_app_number] => 16/170370
[patent_app_country] => US
[patent_app_date] => 2018-10-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 55005
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16170370
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/170370 | HER3 ANTIGEN-BINDING MOLECULES | Oct 24, 2018 | Abandoned |
Array
(
[id] => 14501361
[patent_doc_number] => 20190194335
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-06-27
[patent_title] => ANTIBODIES SPECIFIC FOR EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III AND THEIR USES
[patent_app_type] => utility
[patent_app_number] => 16/163243
[patent_app_country] => US
[patent_app_date] => 2018-10-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34842
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16163243
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/163243 | Antibodies specific for epidermal growth factor receptor variant III and their uses | Oct 16, 2018 | Issued |
Array
(
[id] => 17890763
[patent_doc_number] => 11453716
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-27
[patent_title] => Single domain serum albumin binding protein
[patent_app_type] => utility
[patent_app_number] => 16/161986
[patent_app_country] => US
[patent_app_date] => 2018-10-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 14901
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 127
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16161986
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/161986 | Single domain serum albumin binding protein | Oct 15, 2018 | Issued |
Array
(
[id] => 16437146
[patent_doc_number] => 20200354472
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-12
[patent_title] => ANTIBODIES TARGETING GLIOBLASTOMA STEM-LIKE CELLS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/754677
[patent_app_country] => US
[patent_app_date] => 2018-10-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20708
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16754677
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/754677 | Antibodies targeting glioblastoma stem-like cells and methods of use thereof | Oct 8, 2018 | Issued |